Natural history of malignant bone disease in renal cancer: final results of an Italian bone metastasis survey.

Antonio Russo, Giuseppe Badalamenti, Cinzia Ortega, Francesca Maria Tanca, Davide Ottaviani, Camillo Porta, Matteo Santoni, Calogero Mazzara, Andrea Fontana, Maria Antonietta Satolli, Elena Collovà, Giacomo Carteni, Giuseppe Procopio, Gaetano Lanzetta, Roberto Sabbatini, Saverio Cinieri, Evaristo Maiello, Sergio Bracarda, Stefano Luzi Fedeli, Bruno VincenziNicola Silvestris, Vincenzo Adamo, Alfredo Berruti, Toni Ibrahim, Giuseppe Tonini, Rossana Berardi, Sandro Barni, Daniele Santini, Vladimir Virzì, Alessandra Felici

Risultato della ricerca: Article

32 Citazioni (Scopus)

Abstract

BACKGROUND:Bone metastasis represents an increasing clinical problem in advanced renal cell carcinoma (RCC) as disease-related survival improves. There are few data on the natural history of bone disease in RCC.PATIENTS AND METHODS:Data on clinicopathology, survival, skeletal-related events (SREs), and bone-directed therapies for 398 deceased RCC patients (286 male, 112 female) with evidence of bone metastasis were statistically analyzed.RESULTS:Median time to bone metastasis was 25 months for patients without bone metastasis at diagnosis. Median time to diagnosis of bone metastasis by MSKCC risk was 24 months for good, 5 months for intermediate, and 0 months for poor risk. Median number of SREs/patient was one, and 71% of patients experienced at least one SRE. Median times to first, second, and third SRE were 2, 5, and 12 months, respectively. Median survival was 12 months after bone metastasis diagnosis and 10 months after first SRE. Among 181 patients who received zoledronic acid (ZOL), median time to first SRE was significantly prolonged versus control (n = 186) (3 months vs 1 month for control; P<0.05).CONCLUSIONS:RCC patients with bone metastasis are at continuous risk of SREs, and in this survey ZOL effectively reduced this risk.
Lingua originaleEnglish
Numero di pagine7
RivistaPLoS One
Volume8
Stato di pubblicazionePublished - 2013

Fingerprint

kidney neoplasms
bone diseases
Kidney Neoplasms
Bone Diseases
metastasis
Bone
bones
Neoplasm Metastasis
Bone and Bones
zoledronic acid
kidney cells
Renal Cell Carcinoma
carcinoma
Survival
Surveys and Questionnaires
acids
Cells
therapeutics

All Science Journal Classification (ASJC) codes

  • Biochemistry, Genetics and Molecular Biology(all)
  • Agricultural and Biological Sciences(all)
  • General

Cita questo

Natural history of malignant bone disease in renal cancer: final results of an Italian bone metastasis survey. / Russo, Antonio; Badalamenti, Giuseppe; Ortega, Cinzia; Tanca, Francesca Maria; Ottaviani, Davide; Porta, Camillo; Santoni, Matteo; Mazzara, Calogero; Fontana, Andrea; Satolli, Maria Antonietta; Collovà, Elena; Carteni, Giacomo; Procopio, Giuseppe; Lanzetta, Gaetano; Sabbatini, Roberto; Cinieri, Saverio; Maiello, Evaristo; Bracarda, Sergio; Fedeli, Stefano Luzi; Vincenzi, Bruno; Silvestris, Nicola; Adamo, Vincenzo; Berruti, Alfredo; Ibrahim, Toni; Tonini, Giuseppe; Berardi, Rossana; Barni, Sandro; Santini, Daniele; Virzì, Vladimir; Felici, Alessandra.

In: PLoS One, Vol. 8, 2013.

Risultato della ricerca: Article

Russo, A, Badalamenti, G, Ortega, C, Tanca, FM, Ottaviani, D, Porta, C, Santoni, M, Mazzara, C, Fontana, A, Satolli, MA, Collovà, E, Carteni, G, Procopio, G, Lanzetta, G, Sabbatini, R, Cinieri, S, Maiello, E, Bracarda, S, Fedeli, SL, Vincenzi, B, Silvestris, N, Adamo, V, Berruti, A, Ibrahim, T, Tonini, G, Berardi, R, Barni, S, Santini, D, Virzì, V & Felici, A 2013, 'Natural history of malignant bone disease in renal cancer: final results of an Italian bone metastasis survey.', PLoS One, vol. 8.
Russo, Antonio ; Badalamenti, Giuseppe ; Ortega, Cinzia ; Tanca, Francesca Maria ; Ottaviani, Davide ; Porta, Camillo ; Santoni, Matteo ; Mazzara, Calogero ; Fontana, Andrea ; Satolli, Maria Antonietta ; Collovà, Elena ; Carteni, Giacomo ; Procopio, Giuseppe ; Lanzetta, Gaetano ; Sabbatini, Roberto ; Cinieri, Saverio ; Maiello, Evaristo ; Bracarda, Sergio ; Fedeli, Stefano Luzi ; Vincenzi, Bruno ; Silvestris, Nicola ; Adamo, Vincenzo ; Berruti, Alfredo ; Ibrahim, Toni ; Tonini, Giuseppe ; Berardi, Rossana ; Barni, Sandro ; Santini, Daniele ; Virzì, Vladimir ; Felici, Alessandra. / Natural history of malignant bone disease in renal cancer: final results of an Italian bone metastasis survey. In: PLoS One. 2013 ; Vol. 8.
@article{1a1f7e7d84da4ee4ac71f741c74d2eba,
title = "Natural history of malignant bone disease in renal cancer: final results of an Italian bone metastasis survey.",
abstract = "BACKGROUND:Bone metastasis represents an increasing clinical problem in advanced renal cell carcinoma (RCC) as disease-related survival improves. There are few data on the natural history of bone disease in RCC.PATIENTS AND METHODS:Data on clinicopathology, survival, skeletal-related events (SREs), and bone-directed therapies for 398 deceased RCC patients (286 male, 112 female) with evidence of bone metastasis were statistically analyzed.RESULTS:Median time to bone metastasis was 25 months for patients without bone metastasis at diagnosis. Median time to diagnosis of bone metastasis by MSKCC risk was 24 months for good, 5 months for intermediate, and 0 months for poor risk. Median number of SREs/patient was one, and 71{\%} of patients experienced at least one SRE. Median times to first, second, and third SRE were 2, 5, and 12 months, respectively. Median survival was 12 months after bone metastasis diagnosis and 10 months after first SRE. Among 181 patients who received zoledronic acid (ZOL), median time to first SRE was significantly prolonged versus control (n = 186) (3 months vs 1 month for control; P<0.05).CONCLUSIONS:RCC patients with bone metastasis are at continuous risk of SREs, and in this survey ZOL effectively reduced this risk.",
author = "Antonio Russo and Giuseppe Badalamenti and Cinzia Ortega and Tanca, {Francesca Maria} and Davide Ottaviani and Camillo Porta and Matteo Santoni and Calogero Mazzara and Andrea Fontana and Satolli, {Maria Antonietta} and Elena Collov{\`a} and Giacomo Carteni and Giuseppe Procopio and Gaetano Lanzetta and Roberto Sabbatini and Saverio Cinieri and Evaristo Maiello and Sergio Bracarda and Fedeli, {Stefano Luzi} and Bruno Vincenzi and Nicola Silvestris and Vincenzo Adamo and Alfredo Berruti and Toni Ibrahim and Giuseppe Tonini and Rossana Berardi and Sandro Barni and Daniele Santini and Vladimir Virz{\`i} and Alessandra Felici",
year = "2013",
language = "English",
volume = "8",
journal = "PLoS One",
issn = "1932-6203",
publisher = "Public Library of Science",

}

TY - JOUR

T1 - Natural history of malignant bone disease in renal cancer: final results of an Italian bone metastasis survey.

AU - Russo, Antonio

AU - Badalamenti, Giuseppe

AU - Ortega, Cinzia

AU - Tanca, Francesca Maria

AU - Ottaviani, Davide

AU - Porta, Camillo

AU - Santoni, Matteo

AU - Mazzara, Calogero

AU - Fontana, Andrea

AU - Satolli, Maria Antonietta

AU - Collovà, Elena

AU - Carteni, Giacomo

AU - Procopio, Giuseppe

AU - Lanzetta, Gaetano

AU - Sabbatini, Roberto

AU - Cinieri, Saverio

AU - Maiello, Evaristo

AU - Bracarda, Sergio

AU - Fedeli, Stefano Luzi

AU - Vincenzi, Bruno

AU - Silvestris, Nicola

AU - Adamo, Vincenzo

AU - Berruti, Alfredo

AU - Ibrahim, Toni

AU - Tonini, Giuseppe

AU - Berardi, Rossana

AU - Barni, Sandro

AU - Santini, Daniele

AU - Virzì, Vladimir

AU - Felici, Alessandra

PY - 2013

Y1 - 2013

N2 - BACKGROUND:Bone metastasis represents an increasing clinical problem in advanced renal cell carcinoma (RCC) as disease-related survival improves. There are few data on the natural history of bone disease in RCC.PATIENTS AND METHODS:Data on clinicopathology, survival, skeletal-related events (SREs), and bone-directed therapies for 398 deceased RCC patients (286 male, 112 female) with evidence of bone metastasis were statistically analyzed.RESULTS:Median time to bone metastasis was 25 months for patients without bone metastasis at diagnosis. Median time to diagnosis of bone metastasis by MSKCC risk was 24 months for good, 5 months for intermediate, and 0 months for poor risk. Median number of SREs/patient was one, and 71% of patients experienced at least one SRE. Median times to first, second, and third SRE were 2, 5, and 12 months, respectively. Median survival was 12 months after bone metastasis diagnosis and 10 months after first SRE. Among 181 patients who received zoledronic acid (ZOL), median time to first SRE was significantly prolonged versus control (n = 186) (3 months vs 1 month for control; P<0.05).CONCLUSIONS:RCC patients with bone metastasis are at continuous risk of SREs, and in this survey ZOL effectively reduced this risk.

AB - BACKGROUND:Bone metastasis represents an increasing clinical problem in advanced renal cell carcinoma (RCC) as disease-related survival improves. There are few data on the natural history of bone disease in RCC.PATIENTS AND METHODS:Data on clinicopathology, survival, skeletal-related events (SREs), and bone-directed therapies for 398 deceased RCC patients (286 male, 112 female) with evidence of bone metastasis were statistically analyzed.RESULTS:Median time to bone metastasis was 25 months for patients without bone metastasis at diagnosis. Median time to diagnosis of bone metastasis by MSKCC risk was 24 months for good, 5 months for intermediate, and 0 months for poor risk. Median number of SREs/patient was one, and 71% of patients experienced at least one SRE. Median times to first, second, and third SRE were 2, 5, and 12 months, respectively. Median survival was 12 months after bone metastasis diagnosis and 10 months after first SRE. Among 181 patients who received zoledronic acid (ZOL), median time to first SRE was significantly prolonged versus control (n = 186) (3 months vs 1 month for control; P<0.05).CONCLUSIONS:RCC patients with bone metastasis are at continuous risk of SREs, and in this survey ZOL effectively reduced this risk.

UR - http://hdl.handle.net/10447/104475

M3 - Article

VL - 8

JO - PLoS One

JF - PLoS One

SN - 1932-6203

ER -